Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

2926 with DOI

1 strong · 20 moderate · 8 weak

Compilations

12026-05-11T16:17:14.967Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

32last ruled 2026-06-04

0 awaiting a ruling

Issued documents

52026-10-19T20:30:18.155Z

notice · info card · emergency

Searches

191 with no results

queries and counts on the build

Claims checked

9370 supported

70 supported · 23 not

Correspondence

0received

consent field ships in Phase 4

Edges

281

derivations recorded for this entity

Complete over 29 sources, 1 compilation, and 32 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/5f-pb-22/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-09-07srcSynthetic cannabimimetic agents metabolized by carboxylesterases.
  4. 2026-09-07srcScreening, quantification, and confirmation of synthetic cannabinoid metabolites in urine by UHPLC-QTOF-MS.
  5. 2026-09-07srcLarge-scale evaluation of ion mobility spectrometry for the rapid detection of synthetic cannabinoid receptor agonists in infused papers in prisons.
  6. 2026-09-07srcSynthetic cannabinoid receptor agonists and their human metabolites in sewage water: Stability assessment and identification of transformation products.
  7. 2026-09-07srcSynthetic Cannabinoid-Associated Multiple Organ Failure: Case Series and Literature Review.
  8. 2026-09-07srcMetabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry.
  9. 2026-09-07srcAnalytical differentiation of quinolinyl- and isoquinolinyl-substituted 1-(5-fluoropentyl)-1H-indole-3-carboxylates: 5F-PB-22 and its ten isomers.
  10. 2026-09-07srcSensitive quantification of 5F-PB-22 and its three metabolites 5F-PB-22 3-carboxyindole, B-22 N-5-hydroxypentyl and PB-22 N-pentanoic acid in authentic urine specimens obtained from four individuals by liquid chromatography-tandem mass spectrometry.
  11. 2026-09-07srcEvidence of enzyme-mediated transesterification of synthetic cannabinoids with ethanol: potential toxicological impact.
  12. 2026-09-07srcAdverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal
  13. 2026-09-07srcDifferentiation and identification of 5F-PB-22 and its isomers.
  14. 2026-09-07srcThree fatalities associated with the synthetic cannabinoids 5F-ADB, 5F-PB-22, and AB-CHMINACA.
  15. 2026-09-07srcEffects of lipophilicity and functional groups of synthetic cannabinoids on their blood concentrations and urinary excretion.
  16. 2026-09-07srcSynthetic cannabinoids: Variety is definitely not the spice of life.
  17. 2026-09-07srcNative CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.
  18. 2026-09-07srcEffects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.
  19. 2026-09-07srcThe First Reported Case of a Synthetic Cannabinoid Ethyl Ester Detected in a Postmortem Blood Toxicological Analysis.
  20. 2026-09-07srcFour postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22.
  21. 2026-09-07src"Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans
  22. 2026-09-07srcSynthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors.
  23. 2026-09-07srcThe adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects
  24. 2026-09-07srcThe synthetic cannabinoids menace: a review of health risks and toxicity.
  25. 2026-09-07srcMetabolic Profile of Synthetic Cannabinoids 5F-PB-22, PB-22, XLR-11 and UR-144 by Cunninghamella elegans.
  26. 2026-09-07srcA systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment
  27. 2026-09-07srcComprehensive Protocol for the Identification and Characterization of New Psychoactive Substances in the Service of Law Enforcement Agencies.
  28. 2026-09-07srcThe Synthetic Cannabinoids THJ-2201 and 5F-PB22 Enhance In Vitro CB1 Receptor-Mediated Neuronal Differentiation at Biologically Relevant Concentrations.
  29. 2026-09-07srcSchedules of Controlled Substances: Placement of PB-22, 5F-PB-22, AB-FUBINACA and ADB-PINACA into Schedule I. Final rule.
  30. 2026-09-07srcSchedules of Controlled Substances: Temporary Placement of Four Synthetic Cannabinoids Into Schedule I
  31. 2026-09-07srcSubstance Details 5F-PB-22 - UNODC
  32. 2026-09-04issueIssued emergency
  33. 2026-09-04issueIssued info_card
  34. 2026-09-04issueIssued notice
  35. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  36. 2026-06-04publicationPublication — backfill
  37. 2026-05-11revisionRevision 1
  38. 2026-05-11absenceSearched ClinicalTrials.gov for "5F-PB-22 synthetic cannabinoid" — no results
  39. 2026-05-11genGeneration — pipeline-v5 · with 1 morepipeline-v5
  40. 2026-05-11rungeneration run

The same entries, as forms: six forms.